Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Fig. 3

ACR20 response over time (observed). ACR calculated with respect to qualifying index study data available for approximately 90% of patients. Italicized data not reported in figure due to low patient numbers. Data for 12-month intervals are reported in the table. Database lock: March 2, 2017. ACR American College of Rheumatology, BID twice daily

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us